Clinical trials: Cardiac Fibrosis
Alzheimer Disease, Late Onset, Stroke
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to implement the…
- Conditions
- Alzheimer Disease, Late Onset, Stroke, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT05407272
- Testing
- Health Education Manual, manual
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wen-Shiou Pan
Atrial Fibrillation, Thrombosis
Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. Emerging data suggests that common genetic variants are associated with the development of AF.
- Conditions
- Atrial Fibrillation, Thrombosis, Stroke, Genetic Predisposition
- Trial name
- ANATOLI-AF (NCT03560219)
- Testing
- Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis
- Volunteers
- 225 people
- Sponsor
- Memorial Ankara Hospital
Sudden Cardiac Death
Dilated Cardiomyopathy - Unknown Therapeutic Risk Reduction by Contempary Medication and Implantable Cardioverter-Defibrillators (DUTCH-ICD)
Research questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate.
- Trial name
- DUTCH-ICD (NCT07415642)
- Testing
- ICD implantation
- Where
- 2 sites in Netherlands
- Volunteers
- 720 people
- Sponsor
- University Medical Center Groningen
Rheumatic Heart Disease, Mitral Stenosis
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
Objective propose: to investigate the effect of Ramipril in suppressing ST2 (suppression of tumorigenicity 2) in the cardiac mitral valve in patients with Rheumatic Heart Disease.
- Conditions
- Rheumatic Heart Disease, Mitral Stenosis, Rheumatic Mitral Stenosis, Fibrosis; Heart
- Trial name
- NCT03991910
- Testing
- Ramipril 5Mg Oral Capsule
- Where
- Indonesia
- Volunteers
- 66 people
- Sponsor
- Universitas Indonesia
Congenital Heart Disease, Heart Failure
Spironolactone in Adult Congenital Heart Disease
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function.
- Conditions
- Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
- Trial name
- NCT01069510
- Testing
- Spironolactone 25mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common genetic cardiomyopathy and remains the leading cause of sudden cardiac death in young people and an important cause of heart failure symptoms and death at any age.
- Trial name
- NCT00879060
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Left Atrial Fibrosis
Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)
The purpose of this study is to validate the technique for the detection of left atrial fibrosis through segmentation of endocardial and epicardium landmarks of the images obtained with 3 Tgadobutrol-enhanced magnetic resonance…
- Trial name
- RESTORE-HV (NCT02274246)
- Testing
- gadobutrol
- Where
- Spain
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
HIV, Diastolic Dysfunction
Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects
In this study, investigators plan to test two potential mechanisms contributing to diastolic dysfunction among asymptomatic persons with HIV who are on cART.
- Conditions
- HIV, Diastolic Dysfunction, Myocardial Fibrosis
- Trial name
- NCT02874703
- Testing
- Cardiac MRI/MRS
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Mitral Valve Prolapse
STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2
Mitral valve prolapse (MVP) is a frequent affection of the mitral valve with a prevalence of 2-3% in the general population. This valvular disease is generally considered as benign, but may at term evolve toward mitral valve…
- Trial name
- STAMP-2 (NCT04852731)
- Testing
- Cardiac MRI, Blood collection, Prolongation of the MRI examination
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Central Hospital, Nancy, France
Atrial Fibrillation, Biomarker
The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several…
- Trial name
- NCT07565337
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
Cirrhosis, Registered on Transplant List
Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.
The aim of this multicenter prospective interventional pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT).
- Trial name
- CARDIOFIBROCIR (NCT06327308)
- Testing
- MRI, Blood sampling
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Atrial Fibrillation
Substrate abLatIon as Concomitant trEatment for Left Atrial Macroreentrant Tachycardia
SLICE-LAMRT is a multicenter, prospective, randomized, double-blind trial that will be carried out in patients older than 18 years with atypical flutter suspected to be of left atrial origin.
- Trial name
- SLICE-LAMRT (NCT05842499)
- Testing
- Line Set Strategy, Conventional strategy
- Where
- Spain
- Volunteers
- 128 people
- Sponsor
- Hospital Universitario 12 de Octubre
Functional Mitral Regurgitation
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)
The goal of this clinical trial is to learn about the effect of dapagliflozin on reducing the degree of mitral regurgitation and myocardial fibrosis in patients with functional mitral regurgitation (FMR) of more than moderate and…
- Trial name
- DEFORM (NCT05848102)
- Testing
- dapagliflozin
- Where
- 3 sites in China
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Congestive Heart Failure
Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease
Hypothesis: Tissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of…
- Trial name
- NCT01099982
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Utah
Congenital Heart Disease, Heart Failure
Gender Difference in NET Activation in Patients With Congenital Heart Disease and Heart Failure
Neutrophil hyperactivation has detrimental effects on cardiac tissue after injuries, leading to fibrosis lesions and cardiac dysfunction.
- Conditions
- Congenital Heart Disease, Heart Failure, Gender
- Trial name
- FIBRONETx (NCT05263843)
- Testing
- Biological markers of myocardial fibrosis
- Where
- 2 sites in France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
The DAPA-STEMI trial investigates whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), reduces heart muscle scarring (fibrosis) and improves heart function after a ST-segment elevation myocardial infarction…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis
- Trial name
- DAPA-STEMI (NCT06619600)
- Testing
- Dapagliflozin
- Where
- 2 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Hospital Clinic of Barcelona
Cardiomyopathy Due to Drug
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity
This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment
- Trial name
- NCT06331806
- Testing
- Evaluation of myocardial fibrosis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Cystic Fibrosis
Sildenafil Exercise: Role of PDE5 Inhibition
Exercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase…
- Trial name
- NCT04039087
- Testing
- Sildenafil 40mg oral capsule
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Jewish Health
Left Ventricular Hypertrophy, Hypertension
Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function.
- Conditions
- Left Ventricular Hypertrophy, Hypertension, Myocardial Fibrosis
- Trial name
- NCT02670031
- Testing
- Cardiovascular Magnetic Resonance, Echocardiogram, Electrocardiogram
- Where
- Singapore
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore